KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Free Cash Flow: 2017-2024

Historic Free Cash Flow for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$35.9 million.

  • Aquestive Therapeutics' Free Cash Flow fell 7.73% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.9 million, marking a year-over-year decrease of 48.21%. This contributed to the annual value of -$35.9 million for FY2024, which is 387.02% down from last year.
  • Aquestive Therapeutics' Free Cash Flow amounted to -$35.9 million in FY2024, which was down 387.02% from -$7.4 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Free Cash Flow ranged from a high of -$7.4 million in FY2023 and a low of -$46.0 million during FY2020.
  • Over the past 3 years, Aquestive Therapeutics' median Free Cash Flow value was -$10.8 million (recorded in 2022), while the average stood at -$18.0 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Free Cash Flow soared by 68.01% in 2022 and then plummeted by 387.02% in 2024.
  • Aquestive Therapeutics' Free Cash Flow (Yearly) stood at -$46.0 million in 2020, then grew by 26.28% to -$33.9 million in 2021, then skyrocketed by 68.01% to -$10.8 million in 2022, then soared by 31.98% to -$7.4 million in 2023, then tumbled by 387.02% to -$35.9 million in 2024.